


I claim:

1. A compound of the following formula:



5

wherein R<sub>2</sub> and R<sub>4</sub> are each independently H, alkyl, halogen;  
R<sub>15</sub> and R<sub>16</sub> are each independently H, alkyl, acyl, alkoxy, aryl, amino, halogen;  
and pharmaceutically acceptable salts and prodrugs thereof.

- 10 2. A compound of claim 1, wherein R<sub>2</sub> is halogen, and R<sub>4</sub> is H.

3. A compound of claim 1, wherein R<sub>2</sub> is H and R<sub>4</sub> is halogen.

4. A compound of claim 1, wherein R<sub>2</sub> and R<sub>4</sub> are H, and R<sub>15</sub> is amino.

15

5. A compound of claim 1, wherein R<sub>2</sub> is H or halogen; R<sub>4</sub> is H or halogen; and R<sub>15</sub> is alkoxy.

6. A compound of claim 1, wherein R<sub>2</sub>, R<sub>4</sub>, R<sub>15</sub> are H or halogen.

20

7. A compound of claim 1, wherein R<sub>2</sub>, R<sub>4</sub> are H or halogen; R<sub>15</sub> is alkyl.



8. A compound of claim 1, wherein R<sub>2</sub> is H, R<sub>4</sub> is H, R<sub>15</sub> is NR<sub>1</sub>R<sub>2</sub>, and R<sub>16</sub> is H.

9. A compound of claim 1, wherein R<sub>16</sub> is HET.




5

10. A compound of claim 9, wherein HET is pyrrolidine, morpholine.


11. A compound of claim 1 having the following structure:




10



5





12. A hormone replacement therapy regimen comprising:

co-administering a therapeutically effective amount of a combination of

5 mammalian estrogen and a compound of any one of claims 1-11 and a pharmaceutically acceptable carrier to a woman having reduced levels of endogenous estrogen.

12. A method for inhibiting or treating coronary heart disease, cardiovascular disease, comprising:

10 administering a therapeutically effective amount of a compound of any one of claims 1-11 and a pharmaceutically acceptable carrier to a patient in need thereof.

13. A method of inhibiting or treating osteoporosis, comprising:

administering a therapeutically effective amount of a compound of any one of

15 claims 1-11 and a pharmaceutically acceptable carrier to a patient in need thereof.

14. A method of inhibiting or treating gastrointestinal disease, comprising:

administering a therapeutically effective amount of a compound of any one of claims 1-11 and a pharmaceutically acceptable carrier to a patient in need thereof.

20

15. A method of inhibiting or treating amebic infections, including giardiasis, comprising:

administering a therapeutically effective amount of a compound of any one of claims 1-11 and a pharmaceutically acceptable carrier to a patient in need thereof.